Hydrogen alleviates right ventricular hypertrophy by inhibiting ferroptosis via restoration of the Nrf2/HO-1 signaling pathway

Figure 1 H₂ inhalation improved body weight and cardiac function in monocrotaline-treated rats. A: Body weight (BW) changes in each group; n = 10; B: BW gain of each group 28 days after monocrotaline (MCT) injection; n = 10; C: Right ventricular ejection fraction (RVEF) of all groups; n = 10; D: Right ventricular (RV) end-diastolic dimension of all groups; n = 10; E: RV end-systolic volume and RV end-diastolic volume of all groups; n = 10; F: RVEF of all groups; n = 10; G: Representative echocardiographic images showing the RV free-wall (RVFW) thickness (at orange arrow, between white lines); n = 10; H: RVFW of each group; n = 10; I: Serum brain natriuretic peptide levels, as assessed by ELISA; n = 10. Data are expressed as the mean ± SD. ^cP < 0.01 MCT group vs control group; ^bP < 0.05 and ^dP < 0.01: MCT+H₂ group vs MCT group. MCT: Monocrotaline; LVEF: Left ventricular ejection fraction; RVEDD: RV end-diastolic dimension; RV-ESV: RV end-systolic volume; RV-EDV: RV end-diastolic volume; RVEF: RV ejection fraction; RVFW: RV free-wall; H₂: Hydrogen.